Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

0A4Y

Aim Immunotech (0A4Y)

Aim Immunotech Inc
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0A4Y
DateTimeSourceHeadlineSymbolCompany
04/10/20247:21AMUK RegulatoryAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerLSE:0A4YAim Immunotech Inc
04/02/20246:30AMUK RegulatoryAIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateLSE:0A4YAim Immunotech Inc
03/26/20248:05AMUK RegulatoryAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastLSE:0A4YAim Immunotech Inc
03/25/20248:05AMUK RegulatoryAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchLSE:0A4YAim Immunotech Inc
03/07/20247:45AMUK RegulatoryAIM ImmunoTech Announces Launch of CEO Corner PlatformLSE:0A4YAim Immunotech Inc
02/29/20247:45AMUK RegulatoryAIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateLSE:0A4YAim Immunotech Inc
02/14/20247:55AMUK RegulatoryAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerLSE:0A4YAim Immunotech Inc
 Showing the most relevant articles for your search:LSE:0A4Y